Mirum Completes Bluejay Therapeutics Acquisition, Adds Late-Stage HDV Asset

summarizeSummary

Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding brelovitug, a late-stage asset for chronic hepatitis delta virus (HDV), and concurrently closed private placement financings totaling $268.5 million to support the integration and development.

check_boxKey Events

• Acquisition Completion

  Mirum finalized the acquisition of Bluejay Therapeutics on January 23, 2026, as previously announced on December 6, 2025.

• Strategic Asset Addition

  The acquisition adds brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV) with FDA Breakthrough Therapy and EMA PRIME designations, to Mirum's pipeline.

• Acquisition Consideration

  The deal includes approximately $306.6 million in cash and 5,195,972 shares of Mirum common stock upfront and as holdback, plus up to $200 million in contingent milestone payments.

• Financing Closure

  Mirum concurrently closed private placement offerings, raising approximately $268.5 million in gross proceeds to support the acquisition and development, following prior announcements on December 8 and December 19, 2025.

auto_awesomeAnalysis

This 8-K confirms the completion of Mirum Pharmaceuticals' strategic acquisition of Bluejay Therapeutics, a move that significantly expands its rare disease pipeline with brelovitug, a promising late-stage asset for chronic hepatitis delta virus (HDV) which holds Breakthrough Therapy and PRIME designations. The acquisition involves substantial upfront and holdback consideration, including approximately $306.6 million in cash and 5,195,972 shares of Mirum common stock, with potential for an additional $200 million in milestone payments. Concurrently, the company closed private placement financings, raising $268.5 million, which will help fund the cash component of the acquisition and support future development. While the acquisition introduces significant dilution and financial outlay, the addition of a late-stage, de-risked asset with high unmet medical need potential is a strong strategic positive for Mirum's long-term growth in the rare disease space. Investors should monitor the progress of brelovitug's AZURE Phase 3 program, with topline data expected in the second half of 2026.